



ANTIMICROBIAL RESISTANCE

Global Report on Surveillance

2014



WHO Library Cataloguing-in-Publication Data

Antimicrobial resistance: global report on surveillance.

1.Anti-infective agents - classification. 2.Anti-infective agents - adverse effects. 3.Drug resistance, microbial - drug effects. 4.Risk management. 5.Humans. I.World Health Organization.

ISBN 978 92 4 156474 8

(NLM classification: QV 250)

© World Health Organization 2014

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications —whether for sale or for non-commercial distribution— should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Credits // Cover photo: ©Shutterstock: © Alex011973 / © Allies Interactive / © Fedorov Oleksiy / © Ivan Cholakov / © Michel Borges / © Vlue //

Design and Layout: www.paprika-annecy.com

Reprinted June 2014 with changes

Printed in France



Contents

Foreword		IX
Summary		X
Acknowledge	ements	XIV
Abbreviations	<u> </u>	XVI
ii iii oddoliori		74174
SECTION	Resistance to antibacterial drugs	
1 01		1
01/	1.1 Background	1
	1.1.1 Limitations	
	1.2 Regional surveillance of antibacterial resistance	3
	1.2.1 WHO African Region	
	1.2.2 WHO Region of the Americas	
	1.2.3 WHO Eastern Mediterranean Region	
	1.2.5 WHO South-East Asia Region	
	1.2.6 WHO Western Pacific Region	
	1.3 References	5
02,	2.1 Availability of national resistance data	9 10
	2.1.1 Key messages.	
	2.2 Resistance data on specific pathogens	12
	2.2.1 Escherichia coli – resistance to third-generation cephalosporins and to fluoroquinolones	15
	2.2.3 Staphylococcus aureus – resistance to methicillin	
	2.2.5 Nontyphoidal <i>Salmonella</i> – resistance to fluoroquinolones	
	2.2.6 Shigella species – resistance to fluoroquinolones.	
	2.2.7 Neisseria gonorrhoeae – decreased susceptibility to third-generation cephalosporins	27
	2.3 References	30
SECTION	The health and economic burden due to antibacterial resistance	
' 03		35
_00/	3.1 Methods	35
	3.2 Findings	36
	3.2.1 Health burden	
	3.2.2 Economic burden	37
	3.3 Knowledge gaps.	39
	3.4 Key messages	40
	3.5 References.	40





Surveillance of	antimicrobial	drug	resistance i	in dise	ease-specific	programmes

Surveillance of antimicrobial drug resistance in disease-specific programmes	
	43
4.1 Tuberculosis	41
4.1.1 Evolution of drug resistance in tuberculosis.	
4.1.2 Surveillance of drug-resistant tuberculosis	
4.1.3 Global public health response to drug-resistant tuberculosis	
4.1.4 Notification of MDR-TB cases and enrolment on treatment	
4.1.5 Public health implications: treatment outcomes for multidrug-resistant	
and extensively drug-resistant tuberculosis	
4.1.6 Key messages.	
4.2 Malaria	
4.2.1 Evolution of antimalarial drug resistance	
4.2.2 Surveillance of antimalarial therapeutic efficacy and resistance	
4.2.3 Global public health implications of antimalarial drug resistance	
, , ,	
4.3 HIV	
4.3.2 Global public health implications of anti-HIV drug resistance	
4.3.3 Key messages.	
4.4 Influenza	
4.4.1 Evolution of resistance in influenza viruses	
4.4.2 Anti-influenza drug resistance	
4.4.3 Surveillance of anti-influenza drug resistance	
4.4.4 Public health implications of anti-influenza drug resistance	
4.4.5 Key messages.	5
4.5 References.	5!
	59
5.1 Antibacterial resistance in food-producing animals and the food chain	59
5.1.1 Ongoing surveillance of antimicrobial resistance in food-producing animals and food	
5.1.2 Integrated surveillance of antimicrobial resistance in foodborne bacteria	
5.1.3 Antimicrobials of particular importance in human and veterinary medicine	
5.1.4 Implications for human health from zoonotic transmission of resistant bacteria and genetic materia 5.1.5 WHO–FAO–OIE tripartite intersectoral collaboration on action	l. 6
5.1.6 Key messages.	
5.2 Antifungal drug resistance: the example of invasive Candidiasis	
5.2.1 Antifungal drug resistance in <i>Candida</i> species	
5.2.2 Antifungal drug resistance surveillance.	
5.2.3 Magnitude of resistance at a global level.	
5.2.5 Key messages	
5.3 References.	6
Conclusions	
	69
6.1 Main findings.	
6.1.1 Current status of resistance to antibacterial drugs.	
6.1.2 Burden of resistance to antibacterial drugs	
6.1.4 Surveillance and present status of antimicrobial drug resistance in disease-specific programmes	
6.1.5 Antibacterial resistance in food-producing animals and the food chain	
6.1.6 Resistance in systemic candidiasis	
6.2 Gaps.	
OLE OUPD	/
6.3 The way forward	7



Annex 1 Methods for collecting data on surveillance and antibacterial resistance

and antibacte	rial resistance	
		73
A1.1 Definitions		73
	n from Member States and networks	
	arch for data in scientific publications	
	neti for data in scientific publications	
A1.4 Neterence		73
Annex 2 Repor	ted or published resistance rates in common bacterial pa	thogens,
, 3		77
A2 Tables:		
A2.1-A2.6	Escherichia coli: Resistance to third-generation cephalosporins	77-87
A2.7-A2.12	Escherichia coli: Resistance to fluoroquinolones	88-96
A2.13-A2.18 A2.19-A2.24	Klebsiella pneumoniae: Resistance to third-generation cephalosporins	97-102
A2.17-A2.24 A2.25-A2.30	Staphylococcus aureus: Resistance to Carbapenenis	
A2.31-A2.36	Streptococcus pneumoniae: Resistance, or non-susceptibility, to penicillin	
A2.37-A2.42	Nontyphoidal Salmonella (NTS): Resistance to fluoroquinolones	
A2.43-A2.48	Shigella species: Resistance to fluoroquinolones	
A2.49-A2.54	Neisseria gonorrhoeae: Decreased susceptibility to third-generation cephalos	porins 143-149
A2.55 References.		150
eviderice (leci	nnical report on methods and detailed results)	169
A3.1 Methods		169
A3.2 Results		171
Appondix 1 O	uestionnaires used for data collection	
Appendix i &c	destrottrialles used for data collection	221
	naire and data template for national antimicrobial resistance (AMR) surveillance naire and data template for antimicrobial resistance (AMR) surveillance networl	
7.p.1.2 dd5511511		
Appendix 2 Wh	HO tools to facilitate surveillance of antibacterial resistance	9
		225
Ap2.1 WHONET		225
	VHO documents for surveillance of AMR	
	des for antimicrobial resistance	
Ap2.4 Referenc	es	229

Appendix 3 Additional international antibacterial resistance surveillance networks

			231
Ap3.1 Networks perforn	ning gene	eral surveillance of antibacterial resistance	231
Ap3.2 References			232





https://www.yunbaogao.cn/report/index/report?reportId=5_27888



